1. Kyoto University Research Information Repository
  2. 060　医学研究科・医学部・医学部附属病院
  3. 泌尿器科紀要
  4. Vol.33 No.10
ダウンロード数: 1095

    このアイテムの引用には次の識別子を使用してください: http://hdl.handle.net/2433/119290
このアイテムのファイル:
ファイル 記述 サイズフォーマット 
33_1728.pdf262.28 kBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド値言語
dc.contributor.author中神, 義三ja
dc.contributor.author林, 昭棟ja
dc.contributor.author伊藤, 博ja
dc.contributor.author平沢, 精一ja
dc.contributor.author淡輪, 邦男ja
dc.contributor.author藤岡, 良彰ja
dc.contributor.author小川, 秀弥ja
dc.contributor.author田中, 求平ja
dc.contributor.author山田, 記道ja
dc.contributor.author石井, 洋二ja
dc.contributor.author引間, 規夫ja
dc.contributor.alternativeNakagami, Yoshizoen
dc.contributor.alternativeLin, Tsaw Tungen
dc.contributor.alternativeIto, Hiroshien
dc.contributor.alternativeHirasawa, Seiichien
dc.contributor.alternativeTannawa, Kunioen
dc.contributor.alternativeFujioka, Yoshiakien
dc.contributor.alternativeOgawa, Hideyaen
dc.contributor.alternativeTanaka, Kyuheien
dc.contributor.alternativeYamada, Norimichien
dc.contributor.alternativeIshii, Yojien
dc.contributor.alternativeHikima, Norioen
dc.date.accessioned2010-06-02T02:26:24Z-
dc.date.available2010-06-02T02:26:24Z-
dc.date.issued1987-10-
dc.identifier.issn0018-1994-
dc.identifier.urihttp://hdl.handle.net/2433/119290-
dc.description.abstractThe safety of prolonged administration of UFT in which tegafur and uracil were mixed in a ratio of 1:4 in molar fraction was studied in 44 cases of bladder cancer and 10 cases of renal cell carcinoma. Daily doses of UFT were 300-600 mg, and average total doses administered were 102.0 g for bladder cancer and 116.6 g for renal cell carcinoma cases. Incidence of adverse effects were 25.0% in bladder cancer and 18.5% in renal cell carcinoma cases. Anorexia, nausea, vomiting and decrease in WBC were observed, but rates of having discontinued the administration of UFT were very low, being 9.1% in bladder cancer and 10.0% in renal cell carcinoma. Thus, UFT was considered to be tolerable during prolonged use in bladder cancer and renal cell carcinoma and also a drug in which more usefulness is expected in multidisciplinary treatments in future.en
dc.format.mimetypeapplication/pdf-
dc.language.isojpn-
dc.publisher泌尿器科紀要刊行会ja
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/therapeutic useen
dc.subjectCarcinoma, Renal Cell/drug therapyen
dc.subjectCarcinoma, Transitional Cell/drug therapyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectKidney Neoplasms/drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectTegafur/administration & dosageen
dc.subjectUracil/administration & dosageen
dc.subjectUrinary Bladder Neoplasms/drug therapyen
dc.subject.ndc494.9-
dc.title膀胱癌, 腎細胞癌に対するUFTの使用経験ja
dc.title.alternativeClinical experience of tegafur-uracil (UFT) against bladder cancer and renal cell carcinomaen
dc.typedepartmental bulletin paper-
dc.type.niitypeDepartmental Bulletin Paper-
dc.identifier.ncidAN00208315-
dc.identifier.jtitle泌尿器科紀要ja
dc.identifier.volume33-
dc.identifier.issue10-
dc.identifier.spage1728-
dc.identifier.epage1732-
dc.textversionpublisher-
dc.sortkey36-
dc.address日本医科大学附属第一病院 泌尿器科ja
dc.address.alternativeDepartment of Urology, First Hospital of Nippon Medical School.en
dc.identifier.pmid3128071-
dcterms.accessRightsopen access-
dc.identifier.pissn0018-1994-
dc.identifier.jtitle-alternativeActa urologica Japonicala
dc.identifier.jtitle-alternativeHinyokika Kiyoen
出現コレクション:Vol.33 No.10

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。